International Journal of Cardiovascular Sciences. 01/Nov/2017;30(6):466-8.
New Cholesterol Targets of SBC Guidelines on Dyslipidemia
DOI: 10.5935/2359-4802.20170090
Evidence from clinical trials and meta-analysis have demonstrated that the most effective LDL (low-density lipoprotein) cholesterol-lowering treatment is associated with unequivocal benefits for reducing atherosclerotic cardiovascular disease (ASCVD) events. More recently, clinical trials concluded that the addition of ezetimibe and of a new class of drugs, inhibitors of proprotein convertase subtilisin/kexine type 9 (iPCSK9), to statins, were able to reduce LDL-C to levels not previously achieved with the available therapy so far.–
Is this context, the results of the IMPROVE-IT study – Improved Reduction of Outcomes: Vytorin Efficacy International Trial, with statins plus ezetimibe compared to statin monotherapy, achieved strict lipid control (LDL-c of 53.7 vs. 69.5 mg/dL, respectively) in patients with acute coronary syndrome, that is, individuals at high cardiovascular risk. In this study, patients achieving LDL-cholesterol levels less than 50 mg/dL had a significantly lower risk of major cardiovascular events compared to patients with LDL cholesterol levels above this value. The risk category was proportionally lower as the level of LDL-C decreased. Although at modest levels, there was an incremental cardiovascular event risk reduction, except mortality.
[…]
2,202